Operational unit Hematology Medical areas of interest Hematology Oncoematology Marrow transplants Stem cell afferences Immunology Research Areas of Interest Clinical Research in Hematology Immunology Specialization hematologist Medical Area Hematology diseases Chronic lymphatic leukemia | Acute lymphoblastic leukemia | Acute myeloid leukemia | Chronic myeloid leukemia | Hodgkin's lymphoma | Non-Hodgkin's lymphoma | Multiple myeloma Professional experiences 2004 - 2006 IRCCS Policlinico Milano Foundation - Milan, Milan, Italy Medical Specialist at the Department of Hematology I and Midollo Transplantation Center, led by Prof. Giorgio Lambertenghi Dellier. He has carried out the following activities: - Outpatient Clinic and Day Hospital Care for Patients with Chronic Lymphocytic Leukemia, Acute Mieloid Leukemia, Acute Lymphoblastic Leukemia, and High Risk Myelodysplasia. It was followed by Tutor Prof. Agostino Cortelezzi. - Outpatient Clinic and Day Hospital Support for autologous and / or allogeneic patients of haematopoietic stem cells or bone marrow and blood donor patients. It was followed by Tutor Prof. Davide Soligo. - Outpatient Clinic and Day Hospital Support for patients with chronic myeloproliferative syndrome, in particular chronic myeloid leukemia. - Clinical Research as Sub-Investigator for Two Bristol-Myers Squibb Phase II Experimental Protocols (a) Ca 180-013 on the Use of "BMS 354825 in Chronic Patients with Leukemia Chronic Chronic PH Resistant or Intolerant to Glivec at high doses "(b) Ca 180-017 randomized" BMS 357825 versus Glivec 800 mg in patients with chronic PH Leukemia Leukemia PH resistant or intolerant to Glivec at standard doses ". - Clinical research for two Novartis protocols "021 023". It was followed by Tutor Prof. Franca Radaelli. - Clinical Research as Sub-Investigator for Two Bristol-Myers Squibb Phase II Experimental Protocols (a) Ca 180-013 on the Use of "BMS 354825 in Chronic Patients with Leukemia Chronic Chronic PH Resistant or Intolerant to Glivec at high doses "(b) Ca 180-017 randomized" BMS 357825 versus Glivec 800 mg in patients with chronic PH Leukemia Leukemia PH resistant or intolerant to Glivec at standard doses ". - Clinical research for two Novartis protocols "021 023". It was followed by Tutor Prof. Franca Radaelli. - Clinical Research as Sub-Investigator for Two Bristol-Myers Squibb Phase II Experimental Protocols (a) Ca 180-013 on the Use of "BMS 354825 in Chronic Patients with Leukemia Chronic Chronic PH Resistant or Intolerant to Glivec at high doses "(b) Ca 180-017 randomized" BMS 357825 versus Glivec 800 mg in patients with chronic PH Leukemia Leukemia PH resistant or intolerant to Glivec at standard doses ". - Clinical research for two Novartis protocols "021 023". It was followed by Tutor Prof. Franca Radaelli. - Clinical research for two Novartis protocols "021 023". It was followed by Tutor Prof. Franca Radaelli. - Clinical research for two Novartis protocols "021 023". It was followed by Tutor Prof. Franca Radaelli. Training 12/11/2007 hematologist 24/07/2002 Degree in medicine and surgery UNIVERSITY OF MILAN

Clinical Research in Hematology Immunology